FDA WARNING_LETTER - SilveryGuy - August 12, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On August 14, 2020, the FDA and FTC issued a Warning Letter to Silveryguy.com, an Amazon Associate, for promoting and participating in the sale of "Colloidal Silver" with unproven COVID-19 claims. The FDA reviewed the company's website (www.silveryguy.com) and Facebook page (www.facebook.com/silveryguy/) on August 5 and 12, 2020.
The violations include marketing Colloidal Silver with claims implying it can mitigate, prevent, treat, diagnose, or cure COVID-19. This causes the product to be an unapproved new drug under Section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and a misbranded drug under Section 502 (21 U.S.C. § 352). Introducing or delivering these products into interstate commerce is prohibited under Sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)), and misbranding a drug held for sale after interstate shipment is prohibited under Section 301(k) (21 U.S.C. § 331(k)).
The letter cites the public health emergency and national emergency declarations related to COVID-19. Sil
ID · b6a70a82-d025-484b-9f8c-4dd2bf619e4d
Full citation text and observation details available on the Dashboard.